1 week Ago By ABMN Staff
Enfusion ( NYSE:ENFN – Free Report ) had its price objective increased by Piper Sandler from $10.00 to $11.50 in a research report sent to investors on Monday morning, Benzinga reports.
Piper Sandler currently has a neutral rating on the stock. Separately, Stifel Nicolaus increased their target price on Enfusion from $11.00 to $13.
00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.
com, the company presently has an average rating of “Hold” and a consensus price target of $10.25. Check Out Our Latest Stock Report on Enfusion Enfusion Trading Down 1.
0 % Insider Buying and Selling at Enfusion In other Enfusion news, COO Neal Pawar sold 21,801 shares of Enfusion stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $10.03, for a total transaction of $218,664.
03. Following the sale, the chief operating officer now directly owns 1,143,544 shares in the company, valued at $11,469,746.32.
The trade was a 1.87 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website .
36.44% of the stock is currently owned by corporate insiders. Hedge Funds Weigh In On Enfusion Institutional investors and hedge funds have recently made changes to their positions in the business.
Barclays PLC increased its position in shares of Enfusion by 251.4% in the 3rd quarter. Barclays PLC now owns 86,039 shares of the company’s stock worth $817,000 after purchasing an additional 61,554 shares during the last quarter.
Geode Capital Management LLC grew its stake in Enfusion by 7.3% in the third quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company’s stock worth $9,770,000 after purchasing an additional 70,367 shares in the last quarter.
Wellington Management Group LLP increased its holdings in Enfusion by 6.7% in the third quarter. Wellington Management Group LLP now owns 976,296 shares of the company’s stock valued at $9,265,000 after buying an additional 61,032 shares during the last quarter.
TenCore Partners LP acquired a new stake in Enfusion during the third quarter valued at approximately $3,938,000. Finally, State Street Corp lifted its holdings in Enfusion by 2.3% during the 3rd quarter.
State Street Corp now owns 952,895 shares of the company’s stock worth $9,043,000 after buying an additional 21,729 shares during the last quarter. 81.05% of the stock is currently owned by hedge funds and other institutional investors.
About Enfusion ( Get Free Report ) Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. See Also Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.
com's FREE daily email newsletter ..
